Neuland Laboratories
BSE:524558 Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
WA
Consensus Narrative from 2 Analysts
Ongoing Capacity Expansions In CDMO And Specialty GDS Set To Strengthen Future Prospects
Key Takeaways New facilities and capacity expansion will drive revenue growth and improve operational efficiency by FY '26. Investment in peptide production and high-value molecules is set to enhance revenue and sustain long-term growth.
View narrative₹17.93k
FV
35.2% undervalued intrinsic discount25.86%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
1 day ago author updated this narrative